Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / / Franziska B. Friske.
Clinical trials of medicinal products on human subjects are a balancing act between the protection of the study participant and the preservation of his dignity on the one hand and the constant striving for medical progress on the other hand. This applies likewise to the control group as an essential...
Saved in:
VerfasserIn: | |
---|---|
Place / Publishing House: | Göttingen : : Universitätsverlag Göttingen,, 2017. |
Year of Publication: | 2017 |
Language: | German |
Physical Description: | 1 online resource (315 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993602840404498 |
---|---|
ctrlnum |
(CKB)5470000002600834 (NjHacI)995470000002600834 (EXLCZ)995470000002600834 |
collection |
bib_alma |
record_format |
marc |
spelling |
Friske, Franziska B., author. Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / Franziska B. Friske. Göttingen : Universitätsverlag Göttingen, 2017. 1 online resource (315 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on: online resource; title from PDF information screen (Worldcat, viewed June 30, 2023). Clinical trials of medicinal products on human subjects are a balancing act between the protection of the study participant and the preservation of his dignity on the one hand and the constant striving for medical progress on the other hand. This applies likewise to the control group as an essential part of every clinical testing of pharmaceuticals without which no drug will receive marketing authorisation in Germany by the competent authorities. Nevertheless, significant gaps in the German legislation concerning this matter still remain as the German legislator has yet to implement any specific rules with regard to the handling and management of the control group in clinical trials. In view of this unsettled legal situation, the author critically analyses the core of the problem areas in this field's current research practice and creates solutions reflecting the interests of the study participant as well as the practical needs of medical research. Only legal clarity regarding the control group can provide for the safety that is crucial in this field of tension between ethics, medicine and the law. Drug testing. |
language |
German |
format |
eBook |
author |
Friske, Franziska B., |
spellingShingle |
Friske, Franziska B., Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / |
author_facet |
Friske, Franziska B., |
author_variant |
f b f fb fbf |
author_role |
VerfasserIn |
author_sort |
Friske, Franziska B., |
title |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / |
title_sub |
Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / |
title_full |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / Franziska B. Friske. |
title_fullStr |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / Franziska B. Friske. |
title_full_unstemmed |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / Franziska B. Friske. |
title_auth |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / |
title_new |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : |
title_sort |
rechtliche zulässigkeit von placebokontrollgruppen in arzneimittelstudien : unter besonderer berücksichtigung der blankoeinwilligung und der zulässigkeit weiterer kontrollvarianten / |
publisher |
Universitätsverlag Göttingen, |
publishDate |
2017 |
physical |
1 online resource (315 pages) |
callnumber-first |
H - Social Science |
callnumber-subject |
HV - Social Pathology, Criminology |
callnumber-label |
HV5823 |
callnumber-sort |
HV 45823 F757 42017 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
615 - Pharmacology & therapeutics |
dewey-full |
615.7040724 |
dewey-sort |
3615.7040724 |
dewey-raw |
615.7040724 |
dewey-search |
615.7040724 |
work_keys_str_mv |
AT friskefranziskab rechtlichezulassigkeitvonplacebokontrollgruppeninarzneimittelstudienunterbesondererberucksichtigungderblankoeinwilligungundderzulassigkeitweitererkontrollvarianten |
status_str |
n |
ids_txt_mv |
(CKB)5470000002600834 (NjHacI)995470000002600834 (EXLCZ)995470000002600834 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien : Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten / |
_version_ |
1796653177673613312 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02164nam a2200265 i 4500</leader><controlfield tag="001">993602840404498</controlfield><controlfield tag="005">20230630203811.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230630s2017 gw o 000 0 ger d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5470000002600834</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995470000002600834</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995470000002600834</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">HV5823</subfield><subfield code="b">.F757 2017</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">615.7040724</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Friske, Franziska B.,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rechtliche Zulässigkeit von Placebokontrollgruppen in Arzneimittelstudien :</subfield><subfield code="b">Unter besonderer Berücksichtigung der Blankoeinwilligung und der Zulässigkeit weiterer Kontrollvarianten /</subfield><subfield code="c">Franziska B. Friske.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Göttingen :</subfield><subfield code="b">Universitätsverlag Göttingen,</subfield><subfield code="c">2017.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (315 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from PDF information screen (Worldcat, viewed June 30, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Clinical trials of medicinal products on human subjects are a balancing act between the protection of the study participant and the preservation of his dignity on the one hand and the constant striving for medical progress on the other hand. This applies likewise to the control group as an essential part of every clinical testing of pharmaceuticals without which no drug will receive marketing authorisation in Germany by the competent authorities. Nevertheless, significant gaps in the German legislation concerning this matter still remain as the German legislator has yet to implement any specific rules with regard to the handling and management of the control group in clinical trials. In view of this unsettled legal situation, the author critically analyses the core of the problem areas in this field's current research practice and creates solutions reflecting the interests of the study participant as well as the practical needs of medical research. Only legal clarity regarding the control group can provide for the safety that is crucial in this field of tension between ethics, medicine and the law.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug testing.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-08 12:08:53 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-06-03 21:39:47 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337400640004498&Force_direct=true</subfield><subfield code="Z">5337400640004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337400640004498</subfield></datafield></record></collection> |